An observational study in Rheumatoid Arthritis -Exposure During Pregnancy, sponsored by Sanofi. Completed at 2 sites in 2 countries. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-17.
Sponsored by Sanofi · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Arthritis, Rheumatoid by Sanofi — 2 open to participants now, 2 under way, none of them phase 3. Arthritis, Rheumatoid · Sanofi.
Among the 36 studies in Arthritis, Rheumatoid by Sanofi, this one is one of 2 that started in 2018, is one of 2 observational ones, and was the 28th registered.
3,334 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →2 of the 36 studies in Arthritis, Rheumatoid by Sanofi are open now, in 6 countries. Recruiting first, the newest first:
Sanofi · Sites in United States
Ages 18+
Sanofi · Sites in Australia, Bosnia and Herzegovina, Georgia and 2 more countries
Ages 18–75
By country, each count listing its studies:
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 12 · Phase 3 10 · Phase 4 4
First in 2002; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 113 is below the median of 176 across 1,017 observational studies indexed under Arthritis, Rheumatoid.
Median enrollment 108 across the 34 interventional studies, 208 across the 2 observational. Of the 34 that completed or were terminated, 14 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 36 studies in Arthritis, Rheumatoid by Sanofi, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To evaluate the relative risk of major structural birth defects, specifically a pattern of anomalies, in sarilumab-exposed pregnancies compared to disease-matched unexposed pregnancies.
Secondary Objective:
To evaluate the risk for sarilumab-exposure relative to the group of healthy pregnant women, and the effect of exposure on other adverse pregnancy and infants outcomes.
Pregnant women enrolled in the study will participate for the duration of that pregnancy. Those who deliver at least one live born infant and the infants will participate for 1 year after delivery of that infant.
Pregnant women enrolled in the study will participate for the duration of that pregnancy. Those who deliver at least one live born infant and the infants will participate for 1 year after delivery of that infant.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
First contact the Registry after prenatal diagnosis of any major structural defect or after pregnancy outcome is known (retrospective data).
Enrolled in this cohort study with a previous pregnancy. Cohort 1: Sarilumab-Exposed Cohort
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Sarilumab-Exposed Cohort: Pregnant women exposed to Kevzara (sarilumab) for the treatment of an approved Kevzara (sarilumab) indication, for any number of days, at any dose, and at any time from the first day of the last menstrual period (LMP) up to and including the end of pregnancy
Drug: Sarilumab SAR153191 (REGN88)
Disease-matched Comparison Cohort: Pregnant women diagnosed with Kevzara (sarilumab) approved indication. Approximate frequency matched to the exposed group by disease indication, validated by medical records, who have not been exposed to Kevzara (sarilumab) any time in the current pregnancy, and have taken another biologic DMARD medication for their disease within 2 years before the current pregnancy and have an indication for such treatment at enrollment
Non-diseased Comparison Cohort: Healthy pregnant women not diagnosed with a Kevzara (sarilumab) indication and unexposed to Kevzara (sarilumab) during the course of the pregnancy
Pharmaceutical form:injection Route of administration: subcutaneous
Also known as: Kevzara
Rate of major structural birth defect
A major structural birth defect is a defect that has either cosmetic or functional significance to the child (eg, a cleft lip) and is identified up to one year of age by the mother, the health care provider/medical record, or identified in the dysmorphological examination.
Time frame: Up to 1 year of age of the infant
Pregnancy Outcomes: Spontaneous abortion
Spontaneous abortion is defined as non-deliberate embryonic or fetal death that occurs \< 20.0 weeks' gestation post-LMP (Last Menstrual period).
Time frame: Date of conception to 20 weeks gestation
Pregnancy Outcomes: Stillbirth
Stillbirth is defined as a non-deliberate fetal death that occurs at or after 20 weeks of gestation but prior to delivery.
Time frame: After 20 weeks of gestation but prior to delivery
Pregnancy Outcomes: Premature delivery
Premature delivery is defined as live birth prior to 37 weeks' gestation as counted from LMP (Last Menstrual period).
Time frame: Live birth prior to 37 weeks gestation
Infant Outcomes: pattern of minor structural birth defects
A specific pattern of 3 or more structural defects in live born infants with dysmorphological physical examination.
Time frame: Up to 1 year of age of the infant
Infant Outcomes: Small for gestational age
Proportion of infants less than or equal to the 10th percentile for sex and gestational age on weight, length, or head circumference.
Time frame: At birth
Infant Outcomes: Postnatal growth deficiency
Proportion of infants less than or equal to the 10th percentile for sex and age on weight, length, or head circumference at 1 year postnatal evaluation.
Time frame: Up to 1 year of age of the infant
Infant Outcomes: Serious or opportunistic infections
Proportion of infants who experienced serious or opportunistic infections up to 1 year of age.
Time frame: Up to 1 year of age of the infant
Infant Outcomes: Hospitalizations
Proportion of infants who experienced hospitalizations in the first year of life excluding those that are linked to premature delivery or birth defects included as endpoints.
Time frame: Up to 1 year of age of the infant
Infant Outcomes: Malignancies
Proportion of infants who reported malignancies reported in an infant after birth and up to 1 year of age.
Time frame: Up to 1 year of age of the infant -
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2018 to primary completion in Dec 2024, 78 months.
Of 155 industry-sponsored observational studies under Arthritis, Rheumatoid, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 113. This study's 78 months is above that.
Counting every sponsor, half of 391 studies reached it within 50 months; a quarter within 25 and three quarters within 113.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.